ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements

Maria M Crespo; Tamara Claridge; Robyn T Domsic; Matthew Hartwig; Jasleen Kukreja; Kathleen Stratton; Kevin M Chan; Maria Molina; Patricia Ging; Adam Cochrane; Konrad Hoetzenecker; Usman Ahmad; Siddhartha Kapnadak; Irina Timofte; Geert Verleden; Dennis Lyu; Sana Quddus; Nicole Davis; Mary Porteous; Jorge Mallea; Michael Perch; Olivier Distler; Kristin Highland; Jesper Magnusson; Robin Vos; Allan R Glanville

doi:10.1016/j.healun.2021.07.013

ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements

Maria M Crespo, Tamara Claridge, Robyn T Domsic, Matthew Hartwig, Jasleen Kukreja, Kathleen Stratton, Kevin M Chan, Maria Molina, Patricia Ging, Adam Cochrane, Konrad Hoetzenecker, Usman Ahmad, Siddhartha Kapnadak, Irina Timofte, Geert Verleden, Dennis Lyu, Sana Quddus, Nicole Davis, Mary Porteous, Jorge MalleaMichael Perch, Olivier Distler, Kristin Highland, Jesper Magnusson, Robin Vos, Allan R Glanville

Department of Cardiology

20 Citations (Scopus)

Abstract

Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.

Original language	English
Journal	The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Volume	40
Issue number	11
Pages (from-to)	1279-1300
Number of pages	22
ISSN	1053-2498
DOIs	https://doi.org/10.1016/j.healun.2021.07.013
Publication status	Published - Nov 2021

Keywords

biologic disease-modifying anti rheumatic drugs
connective tissue diseases
consensus statement
esophageal disorders post-transplant medical and surgical management
feedings
lung transplantation

Access to Document

10.1016/j.healun.2021.07.013

Fingerprint

Dive into the research topics of 'ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements'. Together they form a unique fingerprint.

Cite this

Crespo, M. M., Claridge, T., Domsic, R. T., Hartwig, M., Kukreja, J., Stratton, K., Chan, K. M., Molina, M., Ging, P., Cochrane, A., Hoetzenecker, K., Ahmad, U., Kapnadak, S., Timofte, I., Verleden, G., Lyu, D., Quddus, S., Davis, N., Porteous, M., ... Glanville, A. R. (2021). ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 40(11), 1279-1300. https://doi.org/10.1016/j.healun.2021.07.013

ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. / Crespo, Maria M; Claridge, Tamara; Domsic, Robyn T et al.
In: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, Vol. 40, No. 11, 11.2021, p. 1279-1300.

Research output: Contribution to journal › Journal article › Research › peer-review

Crespo, MM, Claridge, T, Domsic, RT, Hartwig, M, Kukreja, J, Stratton, K, Chan, KM, Molina, M, Ging, P, Cochrane, A, Hoetzenecker, K, Ahmad, U, Kapnadak, S, Timofte, I, Verleden, G, Lyu, D, Quddus, S, Davis, N, Porteous, M, Mallea, J, Perch, M, Distler, O, Highland, K, Magnusson, J, Vos, R & Glanville, AR 2021, 'ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements', The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, vol. 40, no. 11, pp. 1279-1300. https://doi.org/10.1016/j.healun.2021.07.013

Crespo MM, Claridge T, Domsic RT, Hartwig M, Kukreja J, Stratton K et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2021 Nov;40(11):1279-1300. doi: 10.1016/j.healun.2021.07.013

Crespo, Maria M ; Claridge, Tamara ; Domsic, Robyn T et al. / ISHLT consensus document on lung transplantation in patients with connective tissue disease : Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. In: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2021 ; Vol. 40, No. 11. pp. 1279-1300.

@article{047f5486794247858be076bd9156555f,

title = "ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements",

abstract = "Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.",

keywords = "biologic disease-modifying anti rheumatic drugs, connective tissue diseases, consensus statement, esophageal disorders post-transplant medical and surgical management, feedings, lung transplantation",

author = "Crespo, \{Maria M\} and Tamara Claridge and Domsic, \{Robyn T\} and Matthew Hartwig and Jasleen Kukreja and Kathleen Stratton and Chan, \{Kevin M\} and Maria Molina and Patricia Ging and Adam Cochrane and Konrad Hoetzenecker and Usman Ahmad and Siddhartha Kapnadak and Irina Timofte and Geert Verleden and Dennis Lyu and Sana Quddus and Nicole Davis and Mary Porteous and Jorge Mallea and Michael Perch and Olivier Distler and Kristin Highland and Jesper Magnusson and Robin Vos and Glanville, \{Allan R\}",

year = "2021",

month = nov,

doi = "10.1016/j.healun.2021.07.013",

language = "English",

volume = "40",

pages = "1279--1300",

journal = "The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation",

issn = "1053-2498",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - ISHLT consensus document on lung transplantation in patients with connective tissue disease

T2 - Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements

AU - Crespo, Maria M

AU - Claridge, Tamara

AU - Domsic, Robyn T

AU - Hartwig, Matthew

AU - Kukreja, Jasleen

AU - Stratton, Kathleen

AU - Chan, Kevin M

AU - Molina, Maria

AU - Ging, Patricia

AU - Cochrane, Adam

AU - Hoetzenecker, Konrad

AU - Ahmad, Usman

AU - Kapnadak, Siddhartha

AU - Timofte, Irina

AU - Verleden, Geert

AU - Lyu, Dennis

AU - Quddus, Sana

AU - Davis, Nicole

AU - Porteous, Mary

AU - Mallea, Jorge

AU - Perch, Michael

AU - Distler, Olivier

AU - Highland, Kristin

AU - Magnusson, Jesper

AU - Vos, Robin

AU - Glanville, Allan R

PY - 2021/11

Y1 - 2021/11

N2 - Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.

AB - Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.

KW - biologic disease-modifying anti rheumatic drugs

KW - connective tissue diseases

KW - consensus statement

KW - esophageal disorders post-transplant medical and surgical management

KW - feedings

KW - lung transplantation

UR - https://www.scopus.com/pages/publications/85114781488

U2 - 10.1016/j.healun.2021.07.013

DO - 10.1016/j.healun.2021.07.013

M3 - Journal article

C2 - 34474940

SN - 1053-2498

VL - 40

SP - 1279

EP - 1300

JO - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

JF - The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

IS - 11

ER -

ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this